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Mutations in BRCA1 and BRCA2 that cause a dominantly inherited high risk of female breast cancer seem to
explain only a small proportion of the aggregation of the disease. To study the possible additional genetic com-
ponents, we conducted single-locus and two-locus segregation analyses, with and without a polygenic background,
using three-generation families ascertained through 858 women with breast cancer diagnosed at age !40 years,
ascertained through population cancer registries in Melbourne and Sydney, Australia. Extensive testing for dele-
terious mutations in BRCA1 and BRCA2, to date, has identified 34 carriers. Our analysis suggested that, after
other possible unmeasured familial factors are adjusted for and the known BRCA1 and BRCA2 mutation carriers
are excluded, there appears to be a residual dominantly inherited risk of female breast cancer in addition to that
derived from mutations in BRCA1 and BRCA2. This study also suggests that there is a substantial recessively
inherited risk of early-onset breast cancer. According to the best-fitting model, after excluding known carriers of
mutations in BRCA1 and BRCA2, about 1/250 (95% confidence interval [CI] 1/500 to 1/125) women have a
recessive risk of 86% (95% CI 69%–100%) by age 50 years and of almost 100% by age 60 years. Possible reasons
that our study has implicated a novel strong recessive effect include our inclusion of data on lineal aunts and
grandmothers, study of families ascertained through women with early-onset breast cancer, allowance for multiple
familial factors in the analysis, and removal of families for whom the cause (i.e., BRCA1 or BRCA2) is known.
Our findings may have implications for attempts to identify new breast cancer–susceptibility genes.
Introduction
Various studies have shown that family history is an
important risk factor for female breast cancer, especially
if close relatives have early-onset disease (Newman et al.
1988; Claus et al. 1990, 1991; Colditz et al. 1993; Slat-
tery et al. 1993; McCredie et al. 1998). The increased
risk associated with an affected first-degree female rel-
ative varies from about 1.5-fold to 3-fold or more, de-
pending on the age at onset of the relative and the age
of the unaffected at-risk woman (Pharoah et al. 1997).
To explain this extent of familial aggregation, there must
exist a very strong underlying familial risk factor, or
multiple familial risk factors of moderate risk (Peto
Received September 13, 2000; accepted for publication November
28, 2000; electronically published December 27, 2000.
Address for correspondence and reprints: Dr. John Hopper, Centre
for Genetic Epidemiology, The University of Melbourne, 200 Berkeley
Street, Carlton, Victoria 3053, Australia. E-mail: j.hopper@unimelb
.edu.au
 2001 by The American Society of Human Genetics. All rights reserved.
0002-9297/2001/6802-0013$02.00
1980; Hopper and Carlin 1992). Deleterious mutations
in the recently discovered genes BRCA1 (MIM 113705)
and BRCA2 (MIM 600185) that cause a dominantly
inherited high risk appear to explain !20% of familial
aggregation of female breast cancer at age !55 years
(Peto et al. 1999). Currently identified environmental
risk factors, as measured by questionnaires, that are cor-
related within relatives are unlikely to explain 110%
(Hopper and Carlin 1992). Therefore, there is still much
to be learned about why female breast cancer tends to
run in families more often than would be predicted by
chance alone.
Prior to the discovery of BRCA1 and BRCA2, most
segregation analyses of female breast cancer family data
modeled familial aggregation by a single mode of in-
heritance and, without measuring actual genetic vari-
ants, supported the role of rare, highly penetrant, and
dominantly inherited genetic factors (Bishop and Gard-
ner 1980; Newman et al. 1988; Hall et al. 1990; Claus
et al. 1991; Iselius et al. 1991; Eccles et al. 1994; Essioux
et al. 1995). Some more recent segregation analyses,
however, have suggested that a recessive or codominant
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Figure 1 Three-generation family, ascertained through a pro-
band with breast cancer at age !40 years, showing age at onset, death,
or interview, that gives most support for a recessively inherited risk
of breast cancer. The proband has not been found to carry a germline
mutation in either BRCA1 or BRCA2.
pattern of inheritance may also be plausible (Goldstein
and Amos 1990; Chen et al. 1995; Baffoe-Bonnie et al.
2000).
In this article we have conducted segregation analyses
to investigate models of familial aggregation of female
breast cancer that consider together different modes of
inheritance—dominant, recessive, and polygenic—using
three-generation population-based families from Aus-
tralia that are affected by breast cancer (Hopper et al.
1994, 1999a, 1999b;McCredie et al. 1998). These fam-
ilies have been ascertained through incident cases of
breast cancer in women diagnosed before age 40 years
(probands). We have conducted analysis with and with-
out excluding families on the basis of a proband already
found to carry a deleterious mutation in BRCA1 or
BRCA2, following extensive sequencing and mutation
testing carried out over the past 5 years.
Subjects and Methods
Subjects
Each family was ascertained through a woman who
had been recently diagnosed with breast cancer at age
!40 years, reported to the Victoria or New South Wales
cancer registry and living in Melbourne or Sydney, re-
spectively. Between 1992 and 1995, a total of 467 such
families were studied (McCredie et al. 1998), and from
1996–1999 a further 391 such families have been stud-
ied as part of the NIH-funded Cooperative Family Reg-
istry for Breast Cancer Studies (Hopper et al. 1999b),
giving a total of 858 case families.
For each such proband, a face-to-face interview was
used to collect information on a range of known or
putative risk factors. Prior to interview, each proband
was told that we wished to know about any cancers in
each of her adult first- and second-degree relatives. She
was also informed that we wished to interview her adult
living relatives (i.e., her mother, siblings, both maternal
and paternal grandparents, and lineal aunts), and her
cooperation in approaching those relatives was sought.
The same questions asked of the proband—including
“any cancers in relatives?”—were also asked of these
relatives, usually by a telephone interview. That is, the
family’s history of cancer was gathered from a number
of relatives and over a period of time, usually several
months, during which they were encouraged to inves-
tigate their family’s cancer history. For all relatives for
whom there was a report of a cancer, questions about
age and place of residence at diagnosis, as well as age
at time of interview and age at death (if appropriate),
were asked. Censored age was defined as the lesser of
the latter two ages. Verification of all reported family
cancers was sought through cross-linking with cancer
registries, death certificates, and medical records (see
McCredie et al. 1998). Blood samples were collected
from the probands and some relatives. Further details
about the design and conduct of this breast cancer case/
control family study can be found in work by Hopper
et al. (1994), McCredie et al. (1998), and Hopper et al.
(1999a). Although the full study also involved control
families, ascertained through unaffected women chosen
by use of the Australian electoral rolls and studied by
identical processes, the following segregation analyses
use only the data from those families ascertained through
an affected proband (i.e., case families).
Statistical Analysis
The cumulative probability of breast cancer in a de-
fined cohort of relatives of the probands, F(t)p 1
, where is the survivor function, was estimatedS(t) S(t)
by the Kaplan-Meier product-limit method (Kaplan and
Meier 1958), on the basis of disease status and censored
age, and was calculated by use of the statistical software
STATA (STATA 1999). The variance of the product-limit
estimator was estimated by Greenwood’s formula
(Greenwood 1926) and was used to calculate confidence
intervals. This was performed separately for sisters,
mothers, and combined maternal and paternal lineal
aunts.
Complex segregation analyses were performed using
breast cancer status, age at diagnosis or age at interview
or death, and vital status for the proband and her adult
first- and second-degree relatives (see our fig. 1 and fig.
1 of Cui and Hopper [2000]), by use of the software
MENDEL (Lange and Weeks 1988). Under maximum-
likelihood theory, we fitted what traditionally have been
called single-locus and two-locus models of “major
gene” effects with different modes of inheritance (dom-
inant, recessive, and codominant). We also fitted a hy-
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pergeometric polygenic model following Lange (1997),
with and without a single-locus major-gene effect (An-
toniou et al. 2000). To adjust for ascertainment, the
likelihood for each pedigree was conditioned on the pro-
band being affected at her age at diagnosis of breast
cancer.
For a single-locus model, let a represent a disease allele
and assume Mendelian mode of transmission. Let pp
be the population frequency of all disease alleles1 q
at this locus and assume random mating and Hardy-
Weinberg equilibrium at this locus (Elandt-Johnson
1971). Note that, despite its traditional name, this model
may also represent effects with the same mode of in-
heritance at multiple loci—provided that, at each of
these loci, the at-risk group (i.e., Aa or aa for dominant
inheritance or aa for recessive inheritance) is so rare that
it is highly unlikely that more than one locus is con-
tributing to this mode of inheritance of genetic risk
within the same family.
In accordance with Claus et al. (1993) and Ford et al.
(1998), a proportional hazards model was assumed in
which the hazard function of developing breast cancer
at age t for an individual with i disease alleles, ip
, is given by0, 1, 2
l (t)p HR (t)l (t) . (1)i i 0
We set , so that is the genetic hazardHR (t)p 1 HR (t)0 i
ratio for individuals with i alleles, compared with that
of noncarriers (i.e., individuals with no disease alleles)
at age t. We use the term “hazard ratio,” instead of
“relative risk” or “relative hazard,” to be consistentwith
the entry in Encyclopedia of Biostatistics (Benichou
1997, pp. 11–27). We modeled as a step function,HR (t)i
constant within age groups , where .…(t , t ) jp 1, 2,j1 j
Because the focus of this article is female breast cancer
and no cases of male breast cancer were reported to us
in the studied families, we have assumed for the sake of
simplicity that, in males, for all values of i.l (t)p 0i
Let be the population incidence of female breastl(t)
cancer at age t (Australian Institute of Health and Wel-
fare 1999). Then the hazard function for noncarriers is
given by
l(t)
l (t)p , (2)0 2 2(1 q )HR (t) qd
under dominant inheritance, where HR (t)p1
; byHR (t)p HR (t)2 d
l(t)
l (t)p , (3)0 2 2p HR (t) (1 p )r
under recessive inheritance, where andHR (t)p 11
; and byHR (t)p HR (t)2 r
l(t)
l (t)p , (4)0 2 2p HR (t) 2pqHR (t) q2 1
under the codominant model, where andHR (t)1
are not necessarily equal to or each other.HR (t) HR (t)2 0
In MENDEL (Lange and Weeks 1988), we used ,ln (p)
, and as unknown parameters, asln (HR (t)) ln (HR (t))1 2
their distributions are close to normal. Their variance
estimates were obtained from the asymptotic covariance
matrix.
The probability that a female with i disease alleles
develops breast cancer at age t is given by
t1
exp l (s)ds , i[ ]
0
and the probability that a female does not develop breast
cancer before age t is given by
t
exp l (s)ds , i[ ]
0
where indicates the number of disease alleles.ip 0, 1, 2
For a two-locus model, without loss of generality, we
assumed dominant inheritance for the first locus and
recessive inheritance for the second. The interaction be-
tween the effects of these two loci was allowed to be
multiplicative or additive. Under a multiplicative model,
the hazard ratio of carriers of both a dominant and
recessive risk is given by where is the′HR #HR , HRd r d
hazard ratio for carriers of the dominant risk and
the hazard ratio for carriers of the recessive risk.′HR r
Under an additive model, the hazard ratio is HR d
The correlations between the estimates of pairs′HR .r
of model parameters, e.g. the dominant and recessive
allele frequencies, and the dominant and recessive haz-
ard ratios, were estimated from the asymptotic corre-
lation matrix calculated byMENDEL (Lange andWeeks
1988).
We also fitted models that included a single-locus“ma-
jor-gene” effect plus a hypergeometric finite gene com-
ponent, following Cannings et al. (1978), Fernando et
al. (1994), Antoniou et al. (2000), and Lange (1997).
This approach emulates incorporation of a classic “pol-
ygenic liability model” based on an underlying polygen-
ically determined liability. The approach thus attempts
to model familial effects other than those caused by the
putative major-gene effects of a given mode of inheri-
tance. The hypergeometric polygenic model (Cannings
et al. 1978) proposes n independent and additive loci,
each with two equally likely alleles (positive or negative),
and genotypes with the same number of positive alleles
are assumed to be equivalent. Thus, there are 2n 1
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possible genotypes. The genotype of an offspring is de-
termined by independently sampling n alleles, without
replacement from the genotypes of each parent. The
value of these polygenotypes is given by
X n
Pp SD ,
n
2
where X is the number of positive alleles out of and2n
has a binomial distribution with parameter , so that12
is the standard deviation of the polygenic compo-SD
nent. In this analysis, we used , following Anto-np 3
niou et al. (2000). Further details about this method can
be found in Lange (1997) and Fernando et al. (1994).
Because of the computational demands of performing
this modeling, the hazard ratio for the single locus was
assumed to be a constant over all ages. Again, the mode
of inheritance of the major-gene effect was allowed to
be dominant, recessive, or codominant. The age-specific
hazard function was then assumed to be , wherePl (t)ei
is given by equation (1), with given by (2),l (t) l (t)i 0
(3), or (4), respectively.
Nested models were compared using the likelihood
ratio criterion. Otherwise we used the Akaike’s infor-
mation test (Akaike 1974), defined as (max-AICp 2
imum log-likelihood  number of parameters esti-
mated). It serves as a measure for assessing the relative
fits of unnested models by adding a penalty to each log-
likelihood, to reflect the number of parameters estimated
under a particular model. The most parsimoniousmodel
is taken to be that with the smallest AIC. To identify the
families most likely to be contributing to a particular
major-gene effect (dominant, recessive, or codominant),
we calculated the change in log-likelihood for each fam-
ily when that effect was included in the model.
Testing for Mutations in BRCA1 and BRCA2
A considerable amount of testing for mutations in
BRCA1 and BRCA2 has been undertaken in the pro-
bands of these families. For a random sample of 93
probands from the 1992–1995 study, stratified by family
history, the full coding region of BRCA1 was manually
sequenced (Southey et al. 1999). For all 408 probands
in the 1992–1995 study for whom a blood sample was
taken, protein-truncation testing was undertaken for
exon 11 of BRCA1 and exons 10, 11, and 27 of BRCA2
(Hopper et al. 1999a), which cover about two-thirds of
the combined coding regions of BRCA1 and BRCA2.
These probands were also screened for BRCA1 dupli-
cation 13 (theAlu-mediated 6-kb duplication in BRCA1;
see Puget et al. 1999), and for the three ancestral Ash-
kenazi mutations (185delAG and 5382insC in BRCA1
and 6174delT in BRCA2). The same mutation testing
has been undertaken for the 358 probands in the
1996–1999 study from whom a blood sample was ob-
tained. In addition, manual sequencing of the entire cod-
ing region of BRCA1 and BRCA2 has been completed
for 73 probands with two or more first- or second-degree
relatives with breast cancer.
At the time of the segregation analyses reported in this
article, a deleterious mutation had been identified in 34
probands (18 had mutations in BRCA1 only, 15 had
mutations in BRCA2 only, and 1 had both a BRCA1
and a BRCA2 germline mutation; see Tesoriero et al.
1999). A modified segregation analysis of the families
of the 18 probands in the 1992–1995 study found to
carry a protein-truncating mutation in the defined exons
above suggested that the average penetrance of these
mutations was equivalent to a cumulative risk, to age
70 years, of ∼40% (Hopper et al. 1999a). To evaluate
the effect of genetic susceptibility besides that caused by
deleterious mutations in BRCA1 and BRCA2, we con-
ducted the segregation analyses outlined above both on
the full set of families and on the subset of families ex-
cluding the 34 mutation-carrying probands and their
relatives.
Results
Descriptive Statistics and Analysis of Cohorts of
Relatives
The total of 858 families (identified on the basis of
380 probands living in Sydney at diagnosis and of 478
living in Melbourne) contained 13,805 individuals.
There were 6,289 female relatives of the probands, of
whom 361 (6%) had been diagnosed with breast cancer.
The family size, including the proband, was 7–39 in-
dividuals, with a median of 15. One quarter of the fam-
ilies had 120 members, and another quarter had !13
members. Only 5% of families had 125 members, and
another 5% had !10 members. About one-third (245)
of the probands had no sisters, one-third (294) had only
one, and one-third (319) had more than one. On av-
erage, there were ∼1.7 maternal or paternal lineal aunts
per family.
Table 1 shows the number and percentage of the pro-
bands by the number of relatives with breast cancer for
different categories of relationship to the proband, and
table 2 shows the number and percentage of womenwith
breast cancer by age at diagnosis for different categories
of family members. Of the probands, ∼70% (590/858)
did not have any first- or second-degree female relatives
with breast cancer. Five probands had two affected sis-
ters, and one proband had three affected lineal aunts.
Two probands had five affected relatives, and one pro-
band had four.
Of mothers, ∼10% (82/858) had been diagnosed with
breast cancer, as had 3% (32/1113) of sisters, 6% (147/
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Table 1
No. of Probands by Number of Relatives with Breast Cancer, for Different Categories of Relationship to the
Proband
NO. OF
RELATIVES
WITH
BREAST
CANCER
NO. (%) OF PROBANDS WITH AFFECTED FEMALE RELATIVES
Mother Sister Aunt Grandmother First Degree Second Degree Any
0 776 (90.4) 831 (96.8) 736 (85.8) 761 (88.6) 757 (88.2) 657 (76.6) 590 (68.8)
1 82 (9.6) 22 (2.6) 98 (11.4) 94 (11.0) 90 (10.5) 162 (18.9) 199 (23.2)
2 … 5 (0.6) 23 (2.7) 3 (0.4) 9 (1.1) 32 (3.7) 50 (5.8)
3 … … 1 (0.1) … 2 (0.2) 7 (0.8) 16 (1.9)
4 … … … … … … 1 (0.1)
5 … … … … … … 2 (0.2)
Table 2
No. of Women with Breast Cancer, by Age at Diagnosis, for Different Categories
of Family Members
AGE
(years)
NO. (%) OF AFFECTED WOMEN
Proband
( )np 858
Mother
( )np 858
Sister
( )np 1,113
Aunt
( )np 2,602
Grandmother
( )np 1,716
!30 84 (9.8) 1 (1.2) 2 (6.2) 6 (4.1) 1 (1.0)
30–39 774 (90.2) 11 (13.4) 11 (34.4) 25 (17.0) 4 (4.0)
40–49 … 21 (25.6) 18 (56.3) 35 (23.8) 19 (19.0)
50–59 … 24 (29.3) 1 (3.1) 42 (28.6) 24 (24.0)
60–69 … 21 (25.6) … 28 (19.0) 18 (18.0)
70–79 … 4 (4.9) … 10 (6.8) 23 (23.0)
80 … … … 1 (0.7) 11 (11.0)
Total 858 82 32 147 100
2602) of lineal aunts, and 6% (100/1716) of grand-
mothers. The median age at diagnosis of breast cancer
was 36 years (mean 35, SD 3.6) for the probands, 41
years (mean 40, SD 5) for the affected sisters, 51 years
(mean 52, SD 11) for the affected mothers, 52 years
(mean 51, SD 13) for the affected lineal aunts, and 60
years (mean 61, SD 15) for the affected grandmothers.
Figure 2 shows the cumulative probability of breast
cancer for the Australian population, and for cohorts
defined by sisters, mothers, and lineal aunts of the pro-
band. Of Australian women, ∼7% are diagnosed with
breast cancer before age 70 years, and 2% are diagnosed
with breast cancer by age 50 years (Australian Institute
of Health and Welfare 1999). For the sisters, however,
∼10% (95% confidence interval [CI] 7%–14%) were
affected by age 50 years. For mothers, almost 14% (95%
CI 11%–18%) were affected by age 70 years. There
appeared to be a small excess risk in lineal aunts, at least
up to age 50 years, with ∼3% affected by age 50 years
(95% CI 2%–4%).
Segregation Analyses: Single-Locus Models
Table 3 shows the fits for single-locus models on data
from all 858 families. Under dominant inheritance alone,
the allele frequency was estimated to be small (.001).
When estimated as a constant, the hazard ratio was 63
(95% CI 45–89). When allowed to vary by age, the
estimated hazard ratio decreased markedly with age, al-
though this trend was of marginal statistical significance
( ). On the basis of the age-specific hazard-ratioPp .04
estimates, the cumulative probability of breast cancer in
carriers of at least one copy of the disease allele was
49% (95% CI 39%–59%) and 71% (95% CI
57%–85%) at age 50 and 70 years, respectively. On the
basis of the constant hazard-ratio estimate, it was 58%
and 87%, respectively.
Under recessive inheritance alone, the allele frequency
was .07 and the hazard ratio was 116, independent of
age. The cumulative probability of breast cancer in ho-
mozygote carriers was 80% (95% CI 65%–100%) at
age 50 years and virtually 100% at age 70 years. Under
codominance alone, the allele frequencywas close to that
estimated by the recessive model, as was the hazard ratio
for homozygote carriers. The hazard ratio for hetero-
zygote carriers was small and of marginal significance.
On the basis of the AIC, the recessive model was the
most parsimonious.
Table 4 shows corresponding estimates based on the
824 families with the known BRCA1 and BRCA2 mu-
tation carriers and their relatives excluded. Under dom-
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Table 3
Segregation Analysis of Single-Locus Models, Based on All 858 Families
Model
Allele Frequency
(95% CI)
Age
(years) Hazard Ratio (95% CI) Log-Likelihood
Akaike’s
Information
Criterion
Null 0 20 1 2581.49 5162.98
Dominant .0010 (.0004–.0024) 20–29 157.87 (108.78–229.10) 2523.58 5061.16
30–39 60.98 (35.56–104.19)
40–49 27.18 (14.64–50.23)
50–59 20.16 (8.54–47.50)
60–69 10.11 (2.55–40.03)
70 6.96 (1.34–36.11)
Recessive .0721 (.0541–.0961) 20 116.26 (68.39–197.62) 2526.85 5057.71
Codominant .0667 (.0432–.1031) 20 2.06 (1.06–4.01)a 2526.35 5058.64
142.22 (108.08–187.09)b
a Heterozygote mutation carriers compared with normal homozygotes.
b Homozygote mutation carriers compared with normal homozygotes.
Figure 2 Age-specific cumulative probability of breast cancer
for the population, and for sisters, mothers and lineal aunts of the
probands who had breast cancer before age 40 years.
inant inheritance, the allele frequency was reduced by
∼20%, but the hazard-ratio estimates, and hence the
age-specific cumulative probabilities of disease, were lit-
tle changed. Exclusion of the known mutation carriers
and their relatives had little influence on the parameters
estimated under recessive or codominant inheritance. As
in table 3, the recessive model still had the smallest AIC
value. The allele frequency under recessive inheritance
was .07, showing that it was insensitive to exclusion of
families in which a known dominantly inherited riskwas
segregating.
Segregation Analyses: Two-Locus Models
Table 5 shows the fits of the two-locus models: one
with dominant inheritance of risk and the other with
recessive inheritance of risk. As computation of maxi-
mum-likelihood estimates was very time consuming, we
constrained the hazard-ratio estimates to be a constant
for both the dominant and recessive effects. As judged
by likelihood-ratio tests, the two-locus models clearly
gave a better fit than did the single-locus models. Fur-
thermore, the fits were better if it was assumed that the
interaction effects were multiplicative rather than ad-
ditive, especially when the knownmutation carrierswere
excluded.
Comparison of tables 3 and 5 shows that estimates
of the parameters describing the recessive effect were
virtually unchanged by addition of a dominant effect,
under either the multiplicative or the additive assump-
tion for interaction effects, or when the knownmutation
carriers were included or excluded. The cumulative
probability for carriers of the recessive effect was still
99% to age 70 years. The comparison also shows that
the strength of the dominant effect was reduced by add-
ing a recessive effect to the model. Under the multipli-
cative assumption, the hazard ratio went from 63 to 13,
and the cumulative probability of breast cancer to age
70 years in carriers of at least one disease allele from
87% (95% CI 69%–100%) to 56% (95% CI 45%–
67%). The estimated allele frequency of the recessive
effect was stable, ∼.06, irrespective of the model
specification.
Also shown in table 5 are the results of segregation
analyses of the two-locus model based on the 824 fam-
ilies with known BRCA1 and BRCA2 mutation carriers
and their relatives excluded. As previously seen from
comparing the single-locusmodels with andwithoutmu-
tation carriers (tables 3 and 4), the estimated allele fre-
quency for the dominant effect was reduced by ∼20%.
Under the assumption of multiplicative interaction ef-
fects, for both the dominant and recessive effects, the
estimates of hazard ratio were little changed, and the
allele frequency for the recessive effect was also relatively
stable.
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Table 4
Segregation Analysis of Single-Locus Models, Based on 824 Families with Known BRCA1 and BRCA2
Mutation Carriers and Their Relatives Excluded
Model
Allele Frequency
(95% CI)
Age
(years) Hazard Ratio (95% CI) Log-Likelihood
Akaike’s
Information
Criterion
Null 0 20 1 2431.04 4862.08
Dominant .0008 (.0003–.0019) 20–29 179.73 (123.35–259.77) 2376.92 4767.84
30–39 68.31 (39.47–118.19)
40–49 29.96 (15.74–57.04)
50–59 19.79 (7.61–51.52)
60–69 11.73 (2.85–48.52)
70 6.42 (1.25–37.46)
Recessive .0653 (.0501–.0852) 20 131.69 (77.47–223.87) 2379.79 4763.58
Codominant .0579 (.0385–.0871) 20 2.82 (1.15–5.59)a 2378.91 4763.82
161.80 (125.41–208.75)b
a Heterozygote mutation carriers compared with normal homozygotes.
b Homozygote mutation carriers compared with normal homozygotes.
The correlation coefficients between the estimates of
the dominant and recessive allele frequencies were small
and not statistically significant, varying between .02 and
.18 depending both on whether the mutation carrier
families were included or excluded and on whether the
interaction effect was assumed to be multiplicative or
additive. Similarly, the correlation coefficients between
the two estimated hazard ratios, when each fitted as a
constant independent of age, were also not significant
and between .07 and 0.17 across the four scenarios
above.
Figure 3 shows the age-specific cumulative probability
of breast cancer for carriers of a recessively inherited
and a dominantly inherited risk, under the assumptions
of multiplicative interaction effect between the two loci,
on the basis of the 824 families excluding the known
BRCA1 or BRCA2 mutation carrier families. The re-
cessive penetrance increased rapidly from 43% to 86%
to 98% and 99%, at ages 40, 50, 60, and 70 years,
respectively. The corresponding dominant penetrance es-
timates were 5%, 18%, 32%, and 48%, respectively.
From equations (2) and (3), the hazard rate of breast
cancer for noncarriers of the dominant risk was
, which is almost identical to the pop-l (t)p l(t)/1.020
ulation hazard. The hazard rate for noncarriers of the
recessive risk was , and its correspond-l (t)p l(t)/1.630
ing cumulative probability curve is shown in figure 3.
Segregation Analyses: Hypergeometric Polygenic
Models
Table 6 shows the results of fitting models with a
hypergeometric polygenic effect, with or without a ma-
jor-gene effect. The SD estimated under the polygenic
effect–only model provides a general measure of familial
aggregation. It can be seen that SD decreased more when
a recessive effect was included than when a dominant
effect was included, whether or not the known mutation
carrying families were included. Furthermore, although
a codominant effect gives a reduced SD, the additional
decrease in log-likelihood was small and the AIC sug-
gests that the mixed polygenic and recessive model was
preferable. Note also that the parameter estimates that
best describe the recessive effect when a polygenic effect
is included were not dissimilar to the corresponding es-
timates from the single-locus recessive model or the two-
locus recessive and dominant model (tables 3 and 5).
Exclusion of the known mutation-carrying families
reduced the variance ( ) of the polygenic effect by just2SD
. Of the poly-2 2 2100# [1.578  1.533 ]/1.578 p 6%
genic variance remaining after these families had been
excluded, was2 2 2100# [1.533  0.754 ]/1.533 p 76%
explained by addition of the recessive effect, or 100#
by addition of the2 2 2[1.533  1.118 ]/1.533 p 47%
dominant effect.
Table 7 shows the women with breast cancer, their
relationship to the proband, and their age at diagnosis,
for the 10 families for whom the change in log-likelihood
was greatest from adding a recessive major-gene effect
to a null model with no recessive effect, after the known
mutation-carrying families were excluded. All five fam-
ilies with two sisters affected with breast cancer, as well
as all three families with four or more affected relatives,
are in this table. In none of these families has breast
cancer been shown to be due to a mutation in BRCA1
or BRCA2, despite the probands having been fully se-
quenced for both genes.
Discussion
Two major conclusions arise from our analyses of three-
generation population-based families with breast cancer.
First, there appear to be residual dominantly inherited
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Table 5
Segregation Analyses of Two-Locus Models, Assuming the Interaction Effect is Multiplicative or
Additive, Based on All 858 Families and on the 824 Families with Known BRCA1 and BRCA2
Mutation Carriers and Their Relatives Excluded
Interaction,
No. of Families,
and Model
Allele Frequency
(95% CI) Hazard Ratio (95% CI) Log-Likelihood
Akaike’s
Information
Criterion
Multiplicative:
858:
Dominant .0014 (.0008–.0022) 13.24 (3.57–49.03) 2509.22 5026.44
Recessive .0652 (.0404–.1052) 142.23 (108.52–186.41)
824:
Dominant .0011 (.0003–.0045) 10.09 (3.02–50.34) 2361.57 4729.14
Recessive .0629 (.0445–.0888) 161.26 (111.99–232.19)
Additive:
858:
Dominant .0004 (.0001–.0426) 28.34 (11.96–67.13) 2509.56 5027.12
Recessive .0608 (.0284–.1301) 161.63 (123.56–211.42)
824:
Dominant .0003 (.0001–.0013) 5.92 (1.66–53.17) 2362.83 4733.66
Recessive .0652 (.0304–.1401) 166.87 (117.26–237.46)
Figure 3 Age-specific cumulative probabilities of breast cancer
for the population, for carriers of a dominantly inherited and a re-
cessively inherited risk, and for noncarriers of the recessively inherited
risk, with 95% CIs, on the basis of the 824 families with known
BRCA1 and BRCA2 mutation carriers and their relatives excluded,
under the multiplicative two-locus model.
risks for breast cancer in addition to those derived from
mutations in BRCA1 and BRCA2, even when additional
recessive or polygenic effects are allowed for. Over all
families, the dominant effect was represented by a haz-
ard ratio of 13 (95% CI 4–49), equivalent to a cumu-
lative risk, to age 70 years, of 56% (95%CI 45%–67%),
and allele frequency of .0014 (95% CI .0008–.0022).
Analysis of the family history of breast cancer for the
first 18 BRCA1 and BRCA2 mutation carriers detected
in this sample (Hopper et al. 1999a) suggested that the
increased risk in carriers was nine-fold (95% CI
4%–23%), with cumulative risk, to age 70 years, of
40% (95% CI 15%–65%). Reanalysis including the ad-
ditional 16 carriers made little difference to this point
estimate (analyses not shown). That is, the hazard-ratio
estimates from the segregation analyses are consistent
with the analyses based on known mutation-carrying
families. After excluding the currently known mutation
carriers, the estimate of hazard ratio was 10 (95% CI
3–50), and the allele frequency was reduced by ∼20%.
This suggests that there is still substantial dominantly
inherited risk not explained by BRCA1 and BRCA2.
This could be because our mutation testing has yet to
detect all BRCA1 and BRCA2mutation carriers in these
families. It is likely that we have detected more than
two-thirds of the protein-truncating mutations, given
that they appear to be widely scattered across the coding
regions of these genes. Although we have tested for the
large duplication in BRCA1 (Puget et al. 1999), it is
possible that there are other types of deleterious mu-
tations that we have yet to test for. The average sensi-
tivity of past testing methodologies, as applied to the
Breast Cancer Linkage Consortium, has been histori-
cally estimated to be ∼70%. Nevertheless, there could
also be genes other than BRCA1 and BRCA2 that are
associated with a dominantly inherited risk of breast
cancer but have yet to be discovered (see, e.g., Kainu
et al. 2000).
Perhaps of more importance is the suggestion that
there is a substantial recessively inherited risk of early-
onset breast cancer. This effect was evident, and its pa-
rameter estimates were stable, whether or not we in-
cluded a dominant effect or a polygenic effect. Cohort
analysis of the relatives of probands (fig. 2) showed that
the increased risk to sisters of these early-onset probands
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Table 6
Segregation Analyses of Hypergeometric Polygenic Model, with and without a Single-Locus
Effect, Based on All 858 Families and on 824 Families with Known BRCA1 and BRCA2
Mutation Carriers and Their Relatives Excluded
Model and
No. of
Families
Allele
Frequency
Hazard
Ratio
SD of
Genetic
Component Log-Likelihood
Akaike’s
Information
Criterion
Polygenic only:
858 … … 1.578 2529.65 5061.3
824 … … 1.533 2386.07 4774.14
Mixed dominant:
858 .0002 187.9 1.456 2497.47 5000.94
824 .0002 197.4 1.306 2351.95 4709.9
Mixed recessive:
858 .0779 108.2 .837 2488.92 4983.84
824 .0716 123.2 .726 2344.05 4694.1
Mixed codominant:
858 .0572 2.3a .433 2487.88 4983.76
173.8b
824 .0538 2.3a .277 2342.90 4695.8
186.9b
a Heterozygote mutation carriers compared with normal homozygotes.
b Homozygote mutation carriers compared with normal homozygotes.
was greater than the increased risk to mothers (Pp
). Although this could be explained, in part, by.0005
the mothers being parous by definition and, therefore,
at reduced risk of post-menopausal breast cancer, the
difference in risk between mothers and sisters was ev-
ident in the premenopausal years, when the mothers
were not necessarily at reduced risk of breast cancer
(McCredie et al. 1998), and, furthermore, a large pro-
portion (77%) of the sisters were parous anyway. The
observation by us and others of a higher risk to sisters
of cases than to mothers has been interpreted elsewhere
as suggesting an underlying recessive mode of inheri-
tance for breast cancer (Pharoah et al. 1997).
Table 7 shows the families providing the most evi-
dence for a recessive effect. First, these families have
not been found to carry a mutation in BRCA1 or
BRCA2, despite being fully sequenced. Second, they
have either multiple sisters affected, or multiple lineal
aunts affected, if not both. In four of the five families
in which the mother was affected, at least one lineal
aunt was also affected. In the two families with an af-
fected grandmother, she had at least one affected daugh-
ter. Third, the age at onset in these families was early,
with ∼90% at or before age 50 years. Nevertheless, the
average age at diagnosis of the affected mothers and
lineal aunts in these families was 43 years, nearly a
decade younger than the average age of the affected
mothers and lineal aunts in the study, which was 52
years. The average age at diagnosis of these affected
sisters was 39 years, compared to 40 years for all af-
fected sisters in the study. Finally, as the families shown
in table 7 are those most likely to segregate a recessively
inherited risk of breast cancer, they could contribute to
searches for novel recessively inherited breast can-
cer–susceptibility genes using classic linkage analysis
and the parameter estimates from our fits.
The estimated allele frequency of .063 suggests that
1/250 (95% CI 1/500 to 1/125) women have a reces-
sively inherited risk, compared to our estimate of 1/350
(95% CI 1/225 to 1/625) for having a dominantly in-
herited risk, including that due to mutations in BRCA1
and BRCA2. That is, recessive risk carriers may be at
least as common in the population as dominant risk
carriers. According to our fitted model, the risk in
women with a recessive risk was higher than in those
with a dominant risk (see fig. 3), reaching 50% by age
40 years and near certainty by age 60 years.
Our finding of a high recessively inherited risk at
young age, as well as a dominantly inherited risk, is
supported, to some extent, by the recently published
analysis of 389 Icelandic multigeneration pedigrees
with, on average, 19 female members (Baffoe-Bonnie et
al. 2000). The researchers fitted regressive logistic mod-
els that incorporated a background effect caused by the
mother being affected, plus a single-locus “major gene”
effect. They found that codominant inheritance was
preferable to dominant or recessive inheritance alone,
and predicted that the risk of breast cancer to age 60
years was ∼40% in homozygous carriers and 120% in
heterozygous carriers.
The finding of a recessively inherited risk is also sup-
ported by segregation analyses of population-based
families from the United Kingdom (Antoniou et al.
2000). These families were ascertained through 1,484
women diagnosed with breast cancer before age 55
years, and was limited to their first-degree relatives. As
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Table 7
Ages at Diagnosis of All Affected Members of the 10 Families for Whom the Change in
Log-Likelihood was Greatest When a Recessive Effect Was Added to the Null Model
FAMILY ID
AGE AT DIAGNOSIS
(years)
Proband Mother Sister(s) Aunt(s) Grandmother DLLa
M3808 36 … 36, 30 27, 28 (paternal) 35 (paternal) 12.47
S80242 32 47 … 38, 39 (maternal) … 5.21
M3622 35 … 36, 44 … … 4.93
M3133 27 … … 30, 35 (paternal) … 4.89
M3785 34 … 37, 43 … … 4.53
M3511 37 69 37, 40 54, 68 (paternal) … 4.43
M3138 29 34 34 … … 4.32
S80117 29 38 … 37 (maternal) 50 (maternal) 4.19
S80050 34 37 … 36 (maternal) … 3.42
S80225 38 … 42, 46 66 (maternal) … 3.23
a Change in log-likelihood between null model and recessive model.
in our study, extensive testing for mutations in BRCA1
and BRCA2 had been carried out, in this instance using
multiplex heteroduplex analysis. The penetrances of
mutations in BRCA1 and BRCA2 were assumed to be
that estimated from previous analyses of multicase fam-
ilies. A third major-gene effect was fitted, with and with-
out a hypergeometric polygenic effect. The best major-
gene effect was a recessively inherited risk with a
disease-allele frequency of .24 (95% CI .12–.42) and a
cumulative risk, to age 70 years, of 42% ( ;HRp 21
95% CI 12–36). The polygenic model, however, gave
a similarly good fit.
A number of single-locus analyses in earlier studies
suggested that dominant inheritance was the most plau-
sible. These studies, such as the Cancer and SteroidHor-
mone Study, typically used data from nuclear families
only and had little power to detect recessive inheritance
or to discriminate between different modes of inheri-
tance. In addition to the new United Kingdom study
and the multigeneration Icelandic study described
above, there have been other reports supporting reces-
sive or codominant inheritance. An interesting feature
of those analyses was that they used data from families
ascertained through women with particular features,
namely bilateral breast cancer (Goldstein et al. 1987)
and ductal cancer (Goldstein and Amos 1990).
Therefore, there are three possible reasons why our
study has implicated such a strong recessive effect that
does not appear to have been reported previously in the
literature. Our study has been constructed multigener-
ationally by inclusion of both lineal aunts and grand-
mothers of the probands, giving it more power to detect
recessive effects. Second, it has been based on women
with early-onset disease (!10% of Australian women
who develop breast cancer are diagnosed before the age
of 40), for which it is known that the familial risk to
relatives is stronger than for later-onset diseases (Phar-
oah et al. 1997; McCredie et al. 1998). Furthermore,
the sort of recessive effect suggested by our analyses
may not be detectable in families ascertained through
probands with later-onset disease, given the high esti-
mated risk at young ages, and near-full penetrance, by
age 60 years, of this predicted recessive risk. Third, we
have fitted multiple factors, including both recessive and
dominant modes of inheritance, and allowed for back-
ground familial effects as well. This reflects the reali-
zation that there are likely to bemany sources of familial
aggregation of breast cancer. Future analyses of this data
set will attempt to incorporate measured risk factors
from the questionnaire, as well as other measured ge-
netic variants possibly associated with breast cancer,
such as a polymorphism in the CYP17 gene (Spurdle et
al. 2000).
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